Tg Therapeutics (TGTX) Return on Capital Employed (2012 - 2026)

Tg Therapeutics' Return on Capital Employed history runs 15 years deep, the most recent figure standing at 13.48% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 39.0% year-over-year to 13.48% in Q1 2026; TTM through Mar 2026 was 13.48%, a 39.0% increase from a year earlier, with the FY2025 full-year figure at 18.5%, up 695.0% from the prior year.
• Return on Capital Employed declined to 13.48% in Q1 2026 per TGTX's latest filing, from 13.85% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 36.56% in Q2 2024 and bottomed at 143.13% in Q4 2022.
• The 5-year median for Return on Capital Employed is 7.46% (2023), against an average of 38.6%.
• Across the five-year window, Return on Capital Employed sank 4929 bps in 2022 and jumped 17887 bps in 2024, its largest moves.
• Year by year, Return on Capital Employed stood at 143.13% in 2022, then surged by 105 bps to 7.46% in 2023, then gained by 14 bps to 8.54% in 2024, then jumped by 62 bps to 13.85% in 2025, then decreased by 3 bps to 13.48% in 2026.
• Per Business Quant, the three latest TGTX Return on Capital Employed figures stand at 13.48% (Q1 2026), 13.85% (Q4 2025), and 14.54% (Q3 2025).